^
    Back
    Association details:
    Biomarker:RPS26 expression
    Cancer:Cervical Cancer
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Ribosomal protein S26 (RPS26) expression of advanced cervical cancer (CC) to predict response to programmed death-1 inhibitor combination therapy: A secondary analysis of the CIBI308ALTER-C201 trial.

    Published date:
    05/25/2023
    Excerpt:
    The PFS of patients from CIBI308ALTER-C201 trail was significantly longer among patients with RPS26 expression for 2+/3+ than 0/1+ (not reached v 9.877 months, p= 0.0497)….Our study suggested that RPS26 could be novel predictive biomarkers in patients with CC treated with PD-1 inhibitor combination therapy...
    DOI:
    10.1200/JCO.2023.41.16_suppl.e17520